Target intelligence / Profile preview

SNF2 family ATP-dependent chromatin remodeling ATPase (Snf2 ATPase)

Target
Snf2 ATPase
Molecular classification
Chromatin remodeler, Helicase-related enzyme, Enzyme, DNA-dependent ATPase, Transcription regulator
01

Overview

SNF2 family ATP-dependent chromatin remodeling ATPases are enzymes that use the energy released from ATP hydrolysis to modify the structure of chromatin, thereby regulating access to DNA for processes such as transcription, replication, and repair. They are characterized by a conserved ATPase domain with DExD (DEAD) box helicase motifs, though they generally *do not* function as classic DNA helicases for strand separation, but rather translocate along DNA to disrupt or reposition nucleosomes[1][2][3]. The family includes numerous subfamilies and members within eukaryotes, each with additional regulatory domains; for example, the mammalian proteins SMARCA2, SMARCA4 (BRG1), CHD1, and INO80. Mutations or alterations in these proteins are implicated in development, cancer, and other diseases. This entry refers to a **family of proteins**, not a single canonical human gene or protein. For structured, programmatic use, you should select a specific family member for detailed mapping.

Other names
SWI/SNF ATPasechromatin remodeling ATPaseSMARCASNF2-like ATPaseDExD box ATPaseSWI2/SNF2 family protein
02

Mechanism of action

Drugs targeting members of this family typically aim at ATPase inhibition (blocking ATP hydrolysis), inhibition of chromatin remodeling activity, or modulation of protein-protein interactions within chromatin complexes.

03

Biological functions

Chromatin remodelingRegulation of gene expressionDNA repairTranscriptional activation and repressionDNA translocation
04

Disease associations

CancerNeurodevelopmental disorders
05

Safety considerations

Targeting chromatin-remodeling enzymes may lead to broad effects on gene expression and toxicity in normal proliferating cells or tissuesRisk of affecting DNA repair capacity and genomic integrity
06

Interacting drugs

Experimental compounds targeting specific family members (e.g., BRG1/SMARCA4) are under development; no FDA-approved drugs broadly target the entire family.
07

Biomarkers

Mutation or loss of specific ATPases such as SMARCA4Chromatin states (alteration in chromatin accessibility)

Beyond the preview

Go deeper on SNF2 family ATP-dependent chromatin remodeling ATPase (Snf2 ATPase).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNF2 family ATP-dependent chromatin remodeling ATPase (Snf2 ATPase).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call